Status:
COMPLETED
Bone Response to Enzyme Replacement in Gaucher's Disease
Lead Sponsor:
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Gaucher's Disease
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this study is to examine how the skeleton responds to repeated doses of enzyme replacement therapy in patients with type I Gaucher's disease who have had their spleens removed. Gaucher...
Detailed Description
The purpose of this study is to examine the response of the skeleton to repeated infusions of macrophage-targeted glucocerebrosidase (CEREDASE (Trademark) ) in splenectomized patients with type I Gauc...
Eligibility Criteria
Splenectomized Gaucher patients.
Aged 18-45 who have not received enzyme therapy for at least 1 year.
No patients with other illnesses (pulmonary, liver, kidney, bone, hematologic).
Key Trial Info
Start Date :
December 1 1993
Trial Type :
INTERVENTIONAL
End Date :
November 1 2000
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00001416
Start Date
December 1 1993
End Date
November 1 2000
Last Update
September 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, United States, 20892